Immuneering Corporation - Class A (IMRX) analyst actions
Rating and price-target actions on IMRX in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the IMRX overview →
1 measured IMRX analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients | Press release | -0.19% | +0.39% |
Keep exploring
More IMRX: earnings → · SEC filings → · IMRX overview →